Home > Genitourinary Cancers > Renal Cancer
  • FILTER YOUR SEARCH
    Content Type:
  • Renal Cancer

    An Introduction to Renal Cancer

    The treatment landscape for renal cell carcinoma (RCC) has been transformed in recent years. Immune checkpoint inhibitors (ICIs) are becoming the first-line treatment for metastatic disease; and combined administrations of two ICIs or one tyrosine kinase inhibitor plus one ICI have greatly improved survival of clear cell RCC, the most common RCC subtype. Improved understanding of RCC pathology, the microenvironment and the immune system is likely to contribute to the development of new treatment.

    Browse the content below where leading experts, discuss the latest data in video interviews and short articles from our conference hub and browse the selection of peer-reviewed articles from our journal portfolio. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.

    Renal Cancer Content

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar